Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/132910
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Biomarkers in atrial fibrillation: pathogenesis and clinical implications |
Author: | Noubiap, J.J. Sanders, P. Nattel, S. Lau, D.H. |
Citation: | Cardiac Electrophysiology Clinics, 2021; 13(1):221-233 |
Publisher: | Elsevier |
Issue Date: | 2021 |
ISSN: | 1877-9182 1877-9190 |
Statement of Responsibility: | Jean Jacques Noubiap, Prashanthan Sanders, Stanley Nattel, Dennis H. Lau |
Abstract: | Biomarkers derived from the key components of the pathophysiology of atrial fibrillation (AF) and its complications have the potential to play an important role in earlier characterization of AF phenotype and in risk prediction of adverse clinical events, which may translate into improved management strategies. C-reactive protein, natriuretic peptides, cardiac troponins, growth differentiation factor-15, and fibroblast growth factor-23 have been shown to be the most promising biomarkers in AF. Some biomarkers have already been included in clinical risk scores to predict postoperative AF, thromboembolism, major bleeding, and death. Considerably more work is needed to bring these novel biomarkers into routine clinical management of patients with AF. |
Keywords: | Atrial fibrillation; biomarkers; stroke; troponin; BNP; inflammation; oxidative stress; atrial fibrosis |
Rights: | © 2020 Elsevier Inc. All rights reserved. |
DOI: | 10.1016/j.ccep.2020.10.006 |
Grant ID: | NHMRC |
Published version: | http://dx.doi.org/10.1016/j.ccep.2020.10.006 |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.